Rituximab in ANCA-associated vasculitis: Fad or fact?

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


A number of case reports and case series of patients with Wegener's granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome have supported the use of rituximab (RTX) for the treatment of refractory ANCA-associated vasculitis (AAV). Whether B cell depletion with RTX could replace cyclophosphamide as a first-line therapy for patients with severe AAV remains to be proven. Two studies, recently published in the New England Journal of Medicine, have examined the efficacy of RTX in inducing remission in patients with severe AAV.

Original languageEnglish (US)
Pages (from-to)c182-c188
JournalNephron - Clinical Practice
Issue number2
StatePublished - May 2011


  • Cyclophosphamide
  • High-dose glucocorticosteroids
  • Rituximab

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Rituximab in ANCA-associated vasculitis: Fad or fact?'. Together they form a unique fingerprint.

Cite this